MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Medlab Clinical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.60 |
| 52 Week High | AU$14.94 |
| 52 Week Low | AU$6.45 |
| Beta | 1.1 |
| 11 Month Change | 0% |
| 3 Month Change | -4.21% |
| 1 Year Change | -43.59% |
| 33 Year Change | -79.05% |
| 5 Year Change | -91.85% |
| Change since IPO | -78.00% |
Recent News & Updates
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Shareholder Returns
| MDC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | 1.5% |
| 1Y | -43.6% | 10.0% | 17.2% |
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned 11.4% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned -1.5% over the past year.
Price Volatility
| MDC volatility | |
|---|---|
| MDC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MDC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Sean Hall | www.medlab.co |
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.
Medlab Clinical Limited Fundamentals Summary
| MDC fundamental statistics | |
|---|---|
| Market cap | AU$15.07m |
| Earnings (TTM) | -AU$8.32m |
| Revenue (TTM) | AU$1.54m |
9.8x
P/S Ratio-1.8x
P/E RatioIs MDC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDC income statement (TTM) | |
|---|---|
| Revenue | AU$1.54m |
| Cost of Revenue | AU$336.29k |
| Gross Profit | AU$1.20m |
| Other Expenses | AU$9.52m |
| Earnings | -AU$8.32m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.64 |
| Gross Margin | 78.11% |
| Net Profit Margin | -541.67% |
| Debt/Equity Ratio | 0% |
How did MDC perform over the long term?
See historical performance and comparison